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Abstract 
Background: Activin‑A and follistatin regulate the liver and the immune system.
Aims: To measure the effects of treatment with pegylated‑interferon‑α (Peg‑IFN‑α) and ribavirin on the concentra‑
tions of mature activin‑A and follistatin in serum and liver tissue homogenates in rats.
Methods: A total of 28 male Wistar rats were divided equally into four groups as follow: ‘Control group’ (n = 7), 
‘PEG only group’ consisted of those that only received a weekly injection of Peg‑IFN‑α (6 µg/rat) for 4 weeks, ‘RBV 
only group’ received ribavirin only (4 mg/rat/day) orally for 35 days and the last group received both Peg‑IFN‑α and 
ribavirin ‘PEG & RBV group’. The concentrations of candidate proteins in serum and liver samples were measured using 
ELISA.
Results: Pegylated‑interferon‑α decreased activin‑A and increased follistatin significantly in serum and liver of ‘PEG 
only’ and ‘PEG & RBV’ groups compared with the ‘Control’ and ‘RBV only’ groups (P < 0.05). There was no significant 
difference between the ‘RBV only’ and ‘Control’ groups (P > 0.05) in the concentrations of candidate proteins. A sig‑
nificant positive correlations between serum and liver activin‑A (r = 0.727; P = 0.02 × 10−3) and follistatin (r = 0.540; 
P = 0.01) was also detected.
Conclusion: Pegylated‑interferon‑α modulates the production of activin‑A and follistatin by the liver, which is 
reflected and can be detected at the serum level. Further studies are needed to explore the role of Peg‑IFN‑α based 
therapy on the production of activins and follistatin by the liver and immune cells.
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Background
Infection with hepatitis C virus (HCV) is a global health 
problem and it is a leading cause for the development 
of liver fibrosis, cirrhosis and hepatocellular carcinoma 
[1]. Although new antiviral drugs have been developed, 
the treatment of chronic hepatitis C (CHC) could still 
be based on a weekly injection of pegylated interferon-α 
(Peg-IFN-α)-2a or -2b plus a daily weight-based dose of 
ribavirin depending on the progression of liver damage 
and the presence of other extrahepatic manifestations [2–
5]. Furthermore, the new directly acting antiviral drugs 
are expensive and therefore, Peg-IFN-α based therapy 
could be an affordable alternative approach for treatment 
naïve patients with no liver cirrhosis and/or for those liv-
ing in developing countries and for whom access to the 
new therapy is not definite due to the high cost [6, 7].
The development of hepatic complications following 
infection with HCV is due the promotion of adaptive 
immune response by activating T helper (Th)-2 pathway 
[8, 9]. IFN-α alters the immune response in patients with 
CHC from Th2 to a Th1 mediated pattern, which favours 
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the eradication of the virus [10, 11]. IFN-α induces Th1 
response through the modulation of several cytokines 
including IFN-γ, tumour necrosis factor (TNF)-α, inter-
leukins (IL) and transforming growth factor (TGF)-β by 
the hepatocyte and immune cells [12–14].
Activins are members of the TGF-β family and their 
biological activities are tightly regulated by their bind-
ing protein follistatin [15]. Activin-A and follistatin are 
expressed by the hepatocyte and have been described as 
major regulators of liver biology, liver regeneration and 
liver pathology [16]. Additionally, they play an impor-
tant role in the regulation of the immune system and the 
pathogenesis of inflammatory and fibrotic human dis-
eases [17].
Activin-A and follistatin have been proposed as diag-
nostic/prognostic markers for a variety of liver diseases 
since pathological alterations in their serum concentra-
tions have been documented in several liver patholo-
gies, including viral hepatitis B and C, and they correlate 
with the severity of the diseases [18, 19]. We have previ-
ously demonstrated that both CHC and Peg-IFN-α based 
therapy modulate the serum concentrations of activin-A 
and follistatin [20, 21]. Hence, the present pilot study was 
conducted to test our hypothesis that Peg-IFN-α alters 
the serum concentrations of these proteins by regulating 
their production in the liver.
Methods
Drugs
Pegylated interferon-α-2a (Pegasys®, Hoffmann-La Roche, 
Nutley, NJ, USA) was used. The ready to use syringe con-
tains 180  µg/0.5  ml. Ribavirin capsules (Viracure®, 6th 
October Pharm, Egypt) were used and each capsule con-
tains 400 mg of ribavirin.
Study design
All experimental protocols were approved by the Com-
mittee for the Care and Use of Laboratory Animals at 
Umm Al-Qura University and were in accordance with 
the EU Directive 2010/63/EU for animal experiments.
A total of 28 male Wistar rats weighing 250–300  g 
were used. All animals received humane care during 
the study protocol and during euthanasia. The animals 
were divided equally into four groups as follow: the first 
group included seven rats that served as ‘Control group’, 
the second group consisted of those that only received 
Peg-IFN-α ‘PEG only’ group, the third received ribavirin 
monotherapy ‘RBV only’ group and the last group con-
sisted of rats that received both Peg-IFN-α and ribavirin 
dual therapy ‘PEG & RBV’ group.
The study duration was 5  weeks. Peg-IFN-α-2a was 
prepared as previously reported by diluting the con-
tent of a full syringe (0.5 ml) in normal saline to prepare 
a final volume of 10 ml and the final concentration was 
18  µg/ml [22]. Each rat in the ‘PEG only’ and ‘PEG & 
RBV’ groups received a weekly subcutaneous injection 
of 0.33 ml (6 µg/rat/week) for a total of 4  injections/rat. 
One capsule of ribavirin (400 mg) was dissolved in 50 ml 
saline and each rat in the ‘PEG & RBV’ and ‘RBV only’ 
groups received 0.5 ml (4 mg)/day orally using a feeding 
syringe for the whole length of the study similar to the 
highest dose of the drug recommended for human dur-
ing CHC treatment [12 mg/kg (1,200 mg for body weight 
≥75  kg)] [22]. Following four injections, the rats were 
euthanised in the fifth week at the same day the 5th injec-
tion would have been given. Ribavirin was continued till 
the day before euthanasia.
Types of sample
All rats were euthanised on the same day under diethyl 
ether anaesthesia (Fisher Scientific UK Ltd, Loughbor-
ough, UK) a week after the last injection and 4  ml of 
blood were collected in plain tube immediately after cut-
ting the vena cava. Blood samples were centrifuged for 
20 min and the collected serum was stored in −20°C for 
routine biochemistry and measuring the concentrations 
of activin-A and follistatin in serum.
A specimen from the middle lobe of the liver (2 g) was 
obtained from each animal and was immediately used for 
protein extraction using 6  ml of RIPA lysis buffer con-
taining protease inhibitors (Santa-Cruz Biotechnology 
Inc, CA, USA) and electrical homogeniser. All samples 
were centrifuged at 14,000 rpm for 30 min and small ali-
quots (0.5  ml) of the resultant supernatant were placed 
in Eppendorf tubes and stored in −20°C till processed to 
measure the levels of candidate proteins in liver homoge-
nates using ELISA.
Measurement of extracted protein concentrations
The concentrations of the total proteins extracted from 
the liver specimens were measured using the BioSpec-
nano spectrophotometer (Shimadzu Corporation, Tokyo, 
Japan) at 280 OD. All protein samples were diluted using 
normal saline to make a final concentration of 500 µg/ml.
Enzyme linked immunosorbent assay (ELISA)
Enzyme linked immunosorbent assay was used for the 
quantitative measurement of activin-A and follistatin 
(R&D systems, Minneapolis, USA) in serum and liver 
homogenates samples. All samples were processed in 
duplicate and according the manufacturer’s instructions. 
The optical density of the plates was measured within 
10 min using a plate reader at 450 nm and correction at 
560 nm as recommended by the manufacturer.
The lowest detection limit of activin-A by the used kit 
was 3.7  pg/ml and the upper limit was 1,500  pg/ml as 
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reported by the manufacturer. The intra-assay and inter-
assay precisions of the kit were 4.3 and 5.8%, respectively. 
The kit could cross react by 0.2 and 0.45% with inhibin-A 
and activin-AB, respectively. The detection range of the 
follistatin kit was 250–16,000  pg/ml and the minimum 
detectable dose was 83 pg/ml.
Statistical analysis
Statistical analysis of the results was performed using 
SPSS version 16. Normality and homogeneity of data 
were assessed with the Kolmogorov and Smirnoff test 
and Levene test, respectively. One way ANOVA fol-
lowed by Tukey post hoc test or Kruskal–Wallis followed 
by Dunn’s post hoc test were used to compare between 
the different groups depending on the data homogene-
ity. Correlations were determined using Pearson’s test. P 
value < 0.05 was considered significant.
Results
Results of routine biochemistry
There was no significant difference (P > 0.05) using one 
way ANOVA between the different study groups in body 
weight, liver weight, liver enzymes, metabolic profile and 
renal function parameters (Table 1).
Concentrations of serum and liver activin‑A and follistatin
Administration of Peg-IFN-α-2a for 4 weeks significantly 
decreased the concentrations of activin-A and signifi-
cantly increased the concentrations of follistatin at both 
serum and liver levels of the ‘PEG only’ and ‘PEG & RBV’ 
groups compared with ‘Control’ group. Furthermore, sig-
nificant differences were detected between ‘PEG & RBV’ 
and ‘PEG only’ in serum, but not liver, concentrations of 
candidate proteins (Table 2).
There was no significant difference in the concentra-
tions of candidate proteins between the ‘RBV only’ and 
‘Control’ groups at the serum and liver levels. However, 
a significant difference was detected between ‘RBV only’ 
compared with ‘PEG only’ and ‘PEG & RBV’ groups in 
serum and liver concentrations of activin-A and follista-
tin (Figure 1).
Correlations between serum and liver activin‑A 
and follistatin
A significant positive correlation between serum and liver 
concentrations of activin-A (r = 0.727, P = 0.02 × 10−3) 
and follistatin (r = 0.540, P = 0.01) was observed. Serum 
activin-A also correlated negatively and significantly with 
serum follistatin (r = −0.625, P =  0.001) and liver fol-
listatin (r = −0.674, P = 0.001). Additionally, a significant 
negative correlation was seen between liver activin-A and 
serum follistatin (r = −0.560, P = 0.009). However, there 
was a non-significant correlation between liver activin-A 
and liver follistatin (Figure 2).
Table 1 Mean ± SD of body weight, total liver weight, liver enzymes, albumin, renal function and metabolic parameters 
in the different study groups
Control PEG‑IFN Only PEG‑IFN & Ribavirin Ribavirin Only
Body weight (g) 221.57 ± 20.01 231.97 ± 23.01 218.42 ± 13.64 230.1 ± 22.2
Liver weight (g) 11.04 ± 1.26 10.54 ± 1.52 10.27 ± 0.44 10.23 ± 1.5
ALT (U/l) 60.4 ± 16.2 68.8 ± 18.6 53.9 ± 19 64.1 ± 11.5
AST (U/l) 92.4 ± 24.2 129.8 ± 46.7 119 ± 21.6 133 ± 49.8
Albumin (g/dl) 3.4 ± 0.4 3.3 ± 0.5 3.7 ± 0.3 3.5 ± 0.5
Creatinine (mg/dl) 0.22 ± 0.03 0.2 ± 0.06 0.2 ± 0.03 0.19 ± 0.03
Urea (mg/dl) 47.6 ± 5.1 52.3 ± 4 56.6 ± 9.5 47.3 ± 5.8
BUN (mg/dl) 22.2 ± 2.4 24.4 ± 1.9 26.3 ± 4.4 22 ± 2.7
Glucose (mg/dl) 110.7 ± 12.7 118.9 ± 23.1 112.6 ± 12.7 114.5 ± 16.1
Triglycerides (mg/dl) 77.3 ± 20.3 68.3 ± 13.9 63.2 ± 9.5 85 ± 28.5
Cholesterol (mg/dl) 45 ± 7.2 58.5 ± 12.4 62.2 ± 14.5 64.8 ± 9.7
HDL‑C (g/dl) 36.2 ± 9.2 44.3 ± 1.2 52.8 ± 7.8 53.1 ± 7.7
LDL‑C (g/dl) 6.6 ± 1.7 8.14 ± 2.33 7.1 ± 2.5 6.3 ± 1.55
Table 2 Mean  ±  SD of  serum and  liver concentrations 
of activin-A and follistatin in the different groups
a <0.05 compared to control.
b <0.05 compared to PEG only.
c <0.05 compared to PEG & RBV group.
Activin‑A (pg/ml) Follistatin (pg/ml)
Serum Liver Serum Liver
Control 166.5 ± 41.7 216.1 ± 45.7 128.9 ± 40.9 72.6 ± 22.1
PEG only 92.08 ± 15.3a 115.2 ± 37.5a 354.15 ± 91.1a 157.4 ± 28.5a
PEG & RBV 56.5 ± 10.9a, b 112.4 ± 41.6a 212.4 ± 40.4a, b 134.4 ± 38.6a
RBV only 174.7 ± 35.8b, c 281.8 ± 84.2b, c 98.9 ± 33.4b, c 82.2 ± 23.5b, c
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Discussion
To the best of our knowledge, this is the first study to 
report the effect of Peg-IFN-α and ribavirin on serum 
and liver concentrations of activin-A and follistatin in 
experimental animal model. Our results demonstrated a 
significant decrease in activin-A and significant increase 
in follistatin at the serum and liver levels in ‘PEG only’ 
and ‘PEG & RBV’ groups compared with ‘Control’ and 
‘RBV only’ groups. Furthermore, our results showed sig-
nificant correlations between serum and liver activin-A 
and follistatin.
Our findings suggest that Peg-IFN-α ± ribavirin acts on 
the liver to modulate the production of activin-A and fol-
listatin, and the alteration in liver concentrations of both 
proteins following Peg-IFN-α is reflected and detected in 
serum.
Pegylated-interferon-α alters the immune response in 
patients with CHC from Th2 to a Th1 mediated pattern to 
eradicate the viral infection [8]. Activin-A induces devia-
tion of immune responses toward a type 2 phenotype, its 
serum concentrations increase dramatically in patients 
with CHC and they correlate with the serum levels of 
IL-6, TNF-α and the severity of liver damage associated 
with CHC [20, 23]. Another recent study has also shown 
that serum activin-A and follistatin are modulated during 
the treatment of CHC with Peg-IFN-α based therapy and 
that their levels return to normal in the responder group 
[21]. Hence, we have hypothesised that activin-A and fol-
listatin are potential target for Peg-IFN-α based therapy 
[20, 21, 24].
This hypothesis could further be supported by the 
findings of several other reports. For instant, the expres-
sion of toll like receptors-2 and 4, which increases sig-
nificantly following Peg-IFN-α based therapy in patients 
with CHC, are potent regulators of the release of activin-
A [25–27]. Additionally, the production of TNF-α by the 
natural killer cells increases and, serum IL-6 and IL-10 
decreases following Peg-IFN-α [13, 28]. These cytokines 
have also been shown to be regulated by activin-A [29]. 
Moreover, the release of IFN-γ, which plays an important 
role in controlling CHC following Peg-IFN-α based ther-
apy, is regulated by activin-A [30, 31].
The current observations of significant alterations in 
serum and hepatic activin-A and follistatin following 
Figure 1 Mean ± SD of A serum activin‑A, B liver activin‑A, C serum follistatin and D liver follistatin in the different study groups (a = P < 0.05 
compared to control, b = P < 0.05 compared to PEG‑only group, c = P < 0.05 compared to PEG & RBV group).
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Figure 2 Correlation between a serum and liver activin‑A, b serum and liver follistatin, c serum activin‑A and serum follistatin, d serum activin‑A 
and liver follistatin, e liver activin‑A and serum follistatin and f liver activin‑A and follistatin by Pearson’s correlation test.
Page 6 of 8Refaat et al. BMC Res Notes  (2015) 8:265 
the administration of Peg-IFN-α ± RBV provide addi-
tional support for the aforementioned hypothesis 
and they are in agreement with our previous findings 
regarding the effects of Peg-INF-α based therapy on 
serum activin-A and follistatin during the treatment 
of CHC [21, 24]. Additionally, the observed significant 
positive correlations between liver and serum con-
centrations of activin-A and follistatin, suggest that 
the liver is a major source of these proteins in serum 
and alteration in the hepatic production of these pro-
teins following injection of Peg-IFN-α is reflected 
and detected at the serum level. Further studies are 
required to illustrate the mechanism(s) by which Peg-
IFN-α regulate the production of activin-A and follista-
tin by the liver.
Although follistatin is regarded as the activin binding 
protein [32], it appears that the production of follistatin is 
not only driven by activin during inflammation [33, 34]. 
The synthesis and secretion of follistatin are also modu-
lated by other cytokines, including IL-1b, TNF-α and 
IFN-γ [35, 36]. The physiological and pathological activi-
ties of activin-A are usually antagonised by follistatin at 
the cellular and serum levels [32]. Our results agree with 
these findings as they have shown a significant increase 
in hepatic and serum concentrations of follistatin follow-
ing treatment with Peg-IFN-α, suggesting that the drug 
controls the activities of activin-A by decreasing its pro-
duction and increasing its binding protein in liver and 
serum.
Ribavirin monotherapy is not effective in the treat-
ment of CHC and a number of studies have suggested 
that strong antiviral activity is only seen when RBV is 
combined with either IFN-α or Peg-IFN-α. Therefore, a 
synergism between Peg-IFN-α and RBV was suggested 
and has been shown in  vitro [37]. Additionally, it has 
been suggested that RBV may have immune modulatory 
activities, including the regulation of macrophage and T 
helper cells produced cytokines, modulation of the Th1/
Th2 subset balance and the enhancement of the expres-
sion of interferon stimulated genes [38].
Our results support the previous findings as they have 
demonstrated a significant decrease in serum activin-A 
and significant increase in serum follistatin in ‘PEG & 
RBV’ group compared with ‘PEG only’ and ‘RBV only’ 
groups. However, these synergistic alterations were only 
detected at the serum level, suggesting that co-therapy 
with Peg-IFN-α and ribavirin modulate the production of 
the candidate molecules at other organs/systems beside 
the liver that affect the concentrations of these proteins 
at the serum level.
The biological activities of activins are tightly regulated 
by follistatin since the binding of activin to follistatin is 
almost irreversible [15]. Serum activin is commonly 
bound with the long form follistatin (FS-315) [39], while 
the short form (FS-288) has high affinity for cell mem-
brane activins [40]. The currently available ELISA kits 
for the detection of activin-A and follistatin cannot dis-
tinguish between the free and bound forms of both pro-
teins. Furthermore, the follistatin kit measures both the 
long and short forms. Therefore, the reported results in 
our study are shown at the level of total activin-A and fol-
listatin and the development of ELISA kits that measure 
the free form of both proteins would expose precisely the 
effects of Peg-IFN-α on the activity of both proteins.
A limitation of our study that we did not localize the 
expression of the candidate molecules using other tech-
niques (e.g. immunohistochemistry), which would have 
revealed the cellular origin of both proteins in the liver. 
Furthermore, we did not confirm the protein results at 
the gene level using quantitative PCR. Nevertheless, 
activins are dimer proteins that are consisted of two 
β-subunits and therefore both immunohistochemistry 
and quantitative PCR would only reveal alteration in the 
expression of activin βA-subunit and not the mature pro-
tein [15]. Additionally, this was a phase 1 study and we 
plan to conduct further studies to measure the effect(s) 
of Peg-IFN-α on the expression of candidate proteins in a 
rat model of liver fibrosis and cirrhosis.
Conclusion
In conclusion, Peg-IFN-α modulates the production of 
activin-A and follistatin by the liver, which appears to be 
a major source of serum activin-A and follistatin. Altera-
tions in the concentrations of these proteins in the liver 
are reflected and can be detected at the serum level. Fur-
ther studies are needed to explore the role of Peg-IFN-α 
based therapy on the production of activins and follista-
tin by the liver and immune cells.
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